A DSM Nutritional Products ingredient has been shown in a clinical trial to significantly increase bone mineral density in post-menopausal women.
A trial was conducted in collaboration with Creighton University in the US. It took the form of a pilot, randomised, placebo-controlled, double-blind study in 58 healthy, early post-menopausal women.
The clinical trials discovered that DSM's Genivida Bone Blend increased bone mineral density by up to 3.4% in post-menopausal women after only six months' supplementation.
DSM's Genivida Bone Blend is a patent protected combination of Genivida brand pure genistein; omega-3 fatty acids eicosapentaenoic and docosahexaenoic; and vitamins D3 and K1. "The new study provides evidence of the significant health benefits offered by a multi-nutrient solution to a multifactorial health issue such as bone mineral density," says William Black, vice president of new nutritional ingredients at DSM.
"This new evidence complements previous data showing significant menopause symptom (hot flush) relief for post-menopausal women supplementing with Genivida genistein. Genivida therefore potentially offers solutions for the unmet short-term and long-term health needs of mature women."
According to DSM, an ageing population, bone loss and the resulting increased risk of bone fracture is a growing problem globally approximately a third of post-menopausal women in the US and Europe are affected.